Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock price increase, attributed to the announcement of early clinical research results for three CDK inhibitors to be presented at the 2025 ESMO annual meeting [1] Group 1: Stock Performance - The stock price of Tongyuan Kang Pharmaceutical-B rose nearly 7% in the morning session and is currently up 5.82%, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 2: Clinical Research Announcements - The company announced that three CDK inhibitors, TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), will have their early clinical research results presented as posters at the 2025 ESMO annual meeting scheduled for October 17-21 in Berlin, Germany [1] - Additionally, the company’s drug, Aidiotini Tablets (TY-9591), targeting brain metastases in non-small cell lung cancer, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 3: Regulatory Milestones - Aidiotini Tablets, a highly selective small molecule inhibitor developed for classic EGFR mutations, completed patient enrollment of 224 cases for conditional approval by November 2024 and is expected to submit a Pre-NDA application in April 2025, with a formal conditional NDA submission anticipated in Q4 2025 [1]
同源康医药-B午前涨近7% 公司在ESMO年会公布多项CDK抑制剂临床积极数据